| Avadel Pharmaceuticals Announces Publication of RESTORE Data Highlighting Challenges with Twice-Nightly Oxybates and Strong Patient Preference for Once-Nightly LUMRYZ™ Dosing (sodium oxybate) Extended-Release Oral Suspension (CIII) | 09/03 08:00 | globenewswire.com |
| Avadel Pharmaceuticals to Present at Upcoming Investor Conferences | 08/28 08:00 | globenewswire.com |
| Avadel Pharmaceuticals plc (AVDL) Q2 2024 Earnings Call Transcript | 08/09 12:27 | seekingalpha.com |
| Does Avadel (AVDL) Have the Potential to Rally 43.6% as Wall Street Analysts Expect? | 08/05 11:01 | zacks.com |
| Avadel Pharmaceuticals to Join Russell 3000® Index | 06/27 16:05 | globenewswire.com |
| Avadel Pharmaceuticals Shares New LUMRYZ™ (sodium oxybate) For Extended-release Oral Suspension (CIII) Data at SLEEP 2024 | 05/22 08:00 | globenewswire.com |
| Avadel Pharmaceuticals Appoints Naseem Amin, M.D. to its Board of Directors | 05/21 07:00 | globenewswire.com |
| Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2024 Financial Results | 05/08 07:00 | globenewswire.com |
| Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 8 | 05/01 08:00 | globenewswire.com |